Millipore Sigma Vibrant Logo

196876 BAY 41-2272 - CAS 256376-24-6 - Calbiochem

A cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~ 0.1 nM to 100 µM using recombinant soluble guanylate cyclase).

BAY 41-2272 - CAS 256376-24-6 - Calbiochem: SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: 5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine

Primary Target: Soluble guanylate cyclase
View Products on Sigmaaldrich.com
196876
Preis & Verfügbarkeit

Übersicht

Replacement Information

Key Spec Table

CAS #Empirical Formula
256376-24-6C₂₀H₁₇FN₆

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
196876-5MG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Kst.-Ampulle 5 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewA cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~ 0.1 nM to 100 µM using recombinant soluble guanylate cyclase). The mode of activation is NO-independent and appears to be mediated through direct binding to the α1 and α2 subunits. Shown to be effective in treating numerous cardiovascular conditions in animal models. Inhibits phenylephrine-induced constriction of rabbit aortic rings (IC50 = 304 nM) and blocks collagen-induced aggregation of human platelets (IC50 = 36 nM). Does not inhibit phosphodiesterases.
      Catalogue Number196876
      Brand Family Calbiochem®
      Synonyms5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine
      References
      ReferencesBoerrigter, G., et al. 2003. Circulation 107, 686.
      Kalsi, J.S., et al. 2003. J Urol. 169, 761.
      Koglin, M., et al. 2002. Biochem. Biophys. Res. Commun. 292, 1057.
      Becker, E.M., et al. 2001. BMC Pharmacol. 1, 13.
      Stasch, J.P., et al. 2001. Nature 410, 212.
      Product Information
      CAS number256376-24-6
      ATP CompetitiveN
      FormWhite solid
      Hill FormulaC₂₀H₁₇FN₆
      Chemical formulaC₂₀H₁₇FN₆
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetSoluble guanylate cyclase
      Primary Target IC<sub>50</sub>304 nM inhibiting phenylephrine-induced constriction of rabbit aortic rings; 36 nM in blocking collagen-induced aggregation of human platelets
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      196876-5MG 04055977206593

      Documentation

      BAY 41-2272 - CAS 256376-24-6 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      BAY 41-2272 - CAS 256376-24-6 - Calbiochem Analysenzertifikate

      TitelChargennummer
      196876

      Literatur

      Übersicht
      Boerrigter, G., et al. 2003. Circulation 107, 686.
      Kalsi, J.S., et al. 2003. J Urol. 169, 761.
      Koglin, M., et al. 2002. Biochem. Biophys. Res. Commun. 292, 1057.
      Becker, E.M., et al. 2001. BMC Pharmacol. 1, 13.
      Stasch, J.P., et al. 2001. Nature 410, 212.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision05-April-2011 RFH
      Synonyms5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine
      DescriptionA cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~0.1 nM to 100 µM using recombinant soluble guanylate cyclase). The mode of activation is NO-independent and appears to be mediated through direct binding to the α1 and α2 subunits. Shown to be effective in treating numerous cardiovascular conditions in animal models. Inhibits phenylephrine-induced constriction of rabbit aortic rings (IC50 = 304 nM) and blocks collagen-induced aggregation of human platelets (IC50 = 36 nM). Does not inhibit phosphodiesterases.
      FormWhite solid
      CAS number256376-24-6
      Chemical formulaC₂₀H₁₇FN₆
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (10 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesBoerrigter, G., et al. 2003. Circulation 107, 686.
      Kalsi, J.S., et al. 2003. J Urol. 169, 761.
      Koglin, M., et al. 2002. Biochem. Biophys. Res. Commun. 292, 1057.
      Becker, E.M., et al. 2001. BMC Pharmacol. 1, 13.
      Stasch, J.P., et al. 2001. Nature 410, 212.